CN102633713A - Dabigatran etexilate intermediate, preparation method for same and method for preparing dabigatran etexilate - Google Patents
Dabigatran etexilate intermediate, preparation method for same and method for preparing dabigatran etexilate Download PDFInfo
- Publication number
- CN102633713A CN102633713A CN2012100780324A CN201210078032A CN102633713A CN 102633713 A CN102633713 A CN 102633713A CN 2012100780324 A CN2012100780324 A CN 2012100780324A CN 201210078032 A CN201210078032 A CN 201210078032A CN 102633713 A CN102633713 A CN 102633713A
- Authority
- CN
- China
- Prior art keywords
- formula
- compound
- dabigatran ester
- ester
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CCOC(CCN(C(c(cc1NC(C*)=O)ccc1NC)=O)c1ccccn1)=O Chemical compound CCOC(CCN(C(c(cc1NC(C*)=O)ccc1NC)=O)c1ccccn1)=O 0.000 description 2
- OZBOESGNDSVMDK-UHFFFAOYSA-N CCOC(CCN(C(c(cc1)cc2c1[n](C)c(CNc(cc1)ccc1C#N)n2)=O)c1ncccc1)=O Chemical compound CCOC(CCN(C(c(cc1)cc2c1[n](C)c(CNc(cc1)ccc1C#N)n2)=O)c1ncccc1)=O OZBOESGNDSVMDK-UHFFFAOYSA-N 0.000 description 1
- BGLLICFSSKPUMR-UHFFFAOYSA-N CCOC(CCN(C(c(cc1)cc2c1[n](C)c(CNc(cc1)ccc1C(N)=N)n2)=O)c1ncccc1)=O Chemical compound CCOC(CCN(C(c(cc1)cc2c1[n](C)c(CNc(cc1)ccc1C(N)=N)n2)=O)c1ncccc1)=O BGLLICFSSKPUMR-UHFFFAOYSA-N 0.000 description 1
- PCPATNZTKBOKOY-UHFFFAOYSA-N CCOC(CCN(C(c(cc1N)ccc1NC)=O)c1ncccc1)=O Chemical compound CCOC(CCN(C(c(cc1N)ccc1NC)=O)c1ncccc1)=O PCPATNZTKBOKOY-UHFFFAOYSA-N 0.000 description 1
Images
Abstract
The invention relates to a dabigatran etexilate intermediate, a preparation method for the same and a method for preparing dabigatran etexilate, which belong to the technical field of pharmaceutical chemistry and pharmaceutical engineering. The dabigatran etexilate intermediate is represented as a structural formula (2), so that a preparation process for the dabigatran etexilate is simplified, yield and purity of the dabigatran etexilate are high, reaction temperature is low, expensive dehydrating agent is not needed, and good market prospect is provided.
Description
Technical field
The method that the present invention relates to a kind of dabigatran ester midbody and preparation method thereof and adopt this intermediate preparation dabigatran ester belongs to pharmaceutical chemistry, pharmaceutical engineering technical field.
Background technology
The dabigatran ester; English name: Dabigatran etexilate; Chemical name: 3-[[[2-[[[4-[[[(hexyloxy) carbonyl] amino] formamino] phenyl] amino] toluene]-1-methyl isophthalic acid H-benzoglyoxaline-5-yl] carbonyl] (pyridine-2-yl) amino] ethyl propionate, chemical structural formula:
Be the new oral anticoagulant of German Boethringer Ingelhein company research and development, belong to non-peptide Thrombin-like enzyme suppressor factor.
This medicine goes on the market in Germany and Britain in April, 2008 first, acquisition drugs approved by FDA in 2010.Advantages such as this medical instrument has oral, and strong the effect need not special medication monitoring, and drug interaction is few estimate that the tomorrow requirement amount can be bigger.
At present, the preparation method of dabigatran ester mainly contains following two kinds.
1. based on publication number the route of the international patent application of WO9837075.
The step of this route is: with 4-chloro-3-nitrobenzoic acid methyl esters is raw material; Nucleophilic substitution reaction takes place in aqueous methylamine solution; With after the nitrated 4-methylamino-3-Methyl anthranilate that makes of 10%Pd/C reduction; With the condensation under EDCI (being 1-ethyl-(3-dimethylaminopropyl) phosphinylidyne diimmonium salt hydrochlorate) and HOBT (being I-hydroxybenzotriazole) effect of (4-cyano-aniline base) acetate, obtain 3-[2-(4-cyano-aniline base) acetamido]-4-methylamino oil of Niobe again, under the glacial acetic acid effect, obtain benzimidazoles compound; Be hydrolyzed into acid through LiOH again, generate acyl chlorides in the sulfur oxychloride reaction; Acyl chlorides and 3-(pyridine-2-base amido) ethyl propionate reaction obtains cyano compound; Cyano compound is handled with the saturated ethanolic soln of hydrogenchloride and the ethanolic soln of volatile salt in succession, makes amidine compound, and the last and just own ester of chloroformic acid makes the dabigatran ester under the effect of alkali.
Reaction equation is following:
2. be WO2009153215 based on publication number, WO2007071743, WO2007071742, the route of the international patent application of WO2006000353.
The step of this route is: earlier with the 4-aminobenzonitrile successively with oxammonium hydrochloride and sodium ethylate react 4-amino-N, N '-hydroxybenzene carbonamidine reacts generation furodiazole compound with DMC (being methylcarbonate) and sodium ethylate successively; Reaction obtains the parahelium compounds with METHYL BROMOACETATE again; Obtain hydroxy acid through basic hydrolysis; (be N at CDI then; N '-carbonyl dimidazoles) exist down and get benzothiazole compound with 3-[(3-amino-4-methylamino benzoyl-) (pyridine-2-yl) amino] ethyl propionate condensation, behind the Pd/C catalytic reduction again with the hydrochloric acid salify, under alkaline condition and the positive ethyl ester of chloroformic acid react and make the dabigatran ester.
Reaction equation is following:
The subject matter that above-mentioned two kinds of routes exist is: these routes all contain benzoglyoxaline and become the ring step, and this step will adopt dewatering agent usually, and dewatering agent costs an arm and a leg and is unfavorable for reducing cost; Simultaneously, the midbody yield that Cheng Huanhou obtains is lower, and uses dewatering agent can introduce a large amount of impurity, causes midbody purity very low, and finally causes the purity of product dabigatran ester also very low.
Summary of the invention
Technical problem to be solved by this invention is: overcome the problem that prior art exists; A kind of lower dabigatran ester midbody of difficulty for preparing is provided; And the method for all very high this midbody of preparation of a kind of product yield and purity is provided, a kind of method that adopts this intermediate preparation dabigatran ester is provided in addition.
Technical conceive of the present invention is following: the applicant finds that after deliberation causing the not high major cause of prior art products obtained therefrom purity is that its intermediate preparation difficulty is higher, and not only yield is lower and purity is also lower; The applicant is that raw material has solved the problems referred to above smoothly through adopting a kind of new dabigatran ester midbody.
The technical scheme that the present invention solves its technical problem is following:
Dabigatran ester midbody shown in a kind of formula (2),
Wherein, X is selected from chlorine, bromine, iodine.
A kind of above-mentioned dabigatran ester intermediates preparation may further comprise the steps:
Formula (1) compound and formula (A) compound carry out acylation reaction and obtain aforementioned dabigatran ester midbody (being formula (2) compound);
In the formula (A), X is selected from chlorine, bromine, iodine, and R is selected from hydroxyl, chlorine ,-O-CH
2CH
3,
It is raw material that a kind of method for preparing the dabigatran ester, this method adopt above-mentioned dabigatran ester midbody.
Preferably, this method may further comprise the steps:
The first step obtains formula (6) compound with aforementioned dabigatran ester midbody (being formula (2) compound) and the reaction of p-aminophenyl formonitrile HCN;
In second step, formula (6) compound obtains formula (7) compound after hydrogenchloride and volatile salt processing,
The just own ester reaction of formula (7) compound and chloroformic acid obtains the dabigatran ester.
Preferably, this method may further comprise the steps: aforementioned dabigatran ester midbody (being formula (2) compound) and the reaction of formula (5) compound are obtained the dabigatran ester,
Preferably, this method may further comprise the steps:
The first step, reflux is reacted and is obtained reaction solution in solvent with aforementioned dabigatran ester midbody (being formula (2) compound), then with reaction solution concentrate, cooling, suction filtration, the gained solid is formula (15) compound,
Wherein, X is selected from chlorine, bromine, iodine; Said solvent is selected from acetate, ETHYLE ACETATE, THF (THF), methylene dichloride (DCM);
In second step, formula (15) compound and the reaction of p-aminophenyl formonitrile HCN obtain formula (6) compound,
In the 3rd step, formula (6) compound obtains formula (7) compound after hydrogenchloride and volatile salt processing,
The just own ester reaction of formula (7) compound and chloroformic acid obtains the dabigatran ester.
Preferably, this method may further comprise the steps:
The first step, reflux is reacted and is obtained reaction solution in solvent with aforementioned dabigatran ester midbody (being formula (2) compound), then with reaction solution concentrate, cooling, suction filtration, the gained solid is formula (15) compound,
Wherein, X is selected from chlorine, bromine, iodine; Said solvent is selected from acetate, ETHYLE ACETATE, THF (THF), methylene dichloride (DCM);
In second step, formula (15) compound and the reaction of formula (5) compound obtain the dabigatran ester,
The present invention has simplified the preparation technology of dabigatran ester through dabigatran ester midbody shown in the employing formula (2), and products obtained therefrom yield and purity are all higher, and temperature of reaction is lower, need not to use expensive dewatering agent, has good market outlook.
Description of drawings
Fig. 1 is that the embodiment of the invention 1 makes formula (2) compound
1H-NMR figure.
Fig. 2 is that the embodiment of the invention 1 makes formula (2) compound
13C-NMR figure.
Fig. 3 is that the embodiment of the invention 2,5 makes formula (6) compound
1H-NMR figure.
Fig. 4 is that the embodiment of the invention 3,6 makes the dabigatran ester
1H-NMR figure.
Fig. 5 is that the embodiment of the invention 4 makes formula (15) compound
1H-NMR figure.
Fig. 6 is that the embodiment of the invention 4 makes formula (15) compound
13C-NMR figure.
Embodiment
Below in conjunction with embodiment the present invention is described in further detail.But the invention is not restricted to given example.
Experiment material that relates in the following content and reagent then are commercially available article as not specifying.
The present invention provides dabigatran ester midbody shown in a kind of formula (2),
Wherein, X is selected from chlorine, bromine, iodine.
The present invention also provides a kind of above-mentioned dabigatran ester intermediates preparation, may further comprise the steps:
Formula (1) compound and formula (A) compound carry out acylation reaction and obtain aforementioned dabigatran ester midbody (being formula (2) compound);
In the formula (A), X is selected from chlorine, bromine, iodine, and R is selected from hydroxyl, chlorine ,-O-CH
2CH
3,
Preferably; The detailed process of formula (1) compound and formula (A) compound reaction is: the ethyl acetate solution of formula (A) compound is splashed in the tetrahydrofuran solution of formula (1) compound obtain reaction solution earlier; Again reaction solution was reacted 10 hours under 25 ℃-50 ℃ temperature at least; With reaction solution cooling, suction filtration, the gained solid is aforementioned dabigatran ester midbody (being formula (2) compound) then.
Formula (1) compound that above-mentioned preparation method adopts is commercially available article, and name is called: 3-[(3-amino-4-methylamino benzoyl) pyridine-2-base is amino] ethyl propionate is for CAS number: 212322-56-0.
This preparing method's step is simple, and raw material is purchased easily, and adopts lesser temps, and it is high to obtain midbody purity.
The present invention also provides a kind of method for preparing the dabigatran ester, and it is raw material that this method adopts above-mentioned dabigatran ester midbody.
Preferably, this method may further comprise the steps:
The first step, aforementioned dabigatran ester midbody (being formula (2) compound) obtains formula (6) compound with the reaction of p-aminophenyl formonitrile HCN;
In second step, formula (6) compound obtains formula (7) compound after hydrogenchloride and volatile salt processing,
The just own ester reaction of formula (7) compound and chloroformic acid obtains the dabigatran ester.
Preferred; Aforementioned dabigatran ester midbody (being formula (2) compound) with the detailed process of p-aminophenyl formonitrile HCN reaction is: adding aforementioned dabigatran ester midbody (being formula (2) compound), p-aminophenyl formonitrile HCN, potassiumiodide, salt of wormwood obtain reaction solution in solvent dimethylformamide; The reaction solution heating is reacted; With reaction solution cooling, aqueous precipitation, suction filtration, the gained solid is formula (6) compound then.
Preferably, this method may further comprise the steps: aforementioned dabigatran ester midbody (being formula (2) compound) obtains the dabigatran ester with the reaction of formula (5) compound,
Preferred; Aforementioned dabigatran ester midbody (being formula (2) compound) with the detailed process of formula (5) compound reaction is: adding aforementioned dabigatran ester midbody (being formula (2) compound), formula (5) compound, potassiumiodide, salt of wormwood obtain reaction solution in solvent; Reaction solution is heated to 20 ℃-80 ℃ (preferred 30 ℃-40 ℃) to react; Then with reaction solution concentrate, aqueous precipitation, suction filtration, the gained solid is the dabigatran ester; Said solvent is selected from THF, acetonitrile, acetone, N.
Preferably, this method may further comprise the steps:
The first step, react and obtain reaction solution by reflux in solvent for aforementioned dabigatran ester midbody (being formula (2) compound), then with reaction solution concentrate, cooling, suction filtration, the gained solid is formula (15) compound,
Wherein, X is selected from chlorine, bromine, iodine; Said solvent is selected from acetate, ETHYLE ACETATE, THF (THF), methylene dichloride (DCM);
In second step, formula (15) compound and the reaction of p-aminophenyl formonitrile HCN obtain formula (6) compound,
In the 3rd step, formula (6) compound obtains formula (7) compound after hydrogenchloride and volatile salt processing,
The just own ester reaction of formula (7) compound and chloroformic acid obtains the dabigatran ester.
Preferred; The detailed process of formula (15) compound and the reaction of p-aminophenyl formonitrile HCN is: adding formula (15) compound, p-aminophenyl formonitrile HCN, salt of wormwood obtain reaction solution in acetonitrile solvent; The reaction solution heating is reacted; With reaction solution cooling, aqueous precipitation, suction filtration, the gained solid is formula (6) compound then.
Preferably, this method may further comprise the steps:
The first step, react and obtain reaction solution by reflux in solvent for aforementioned dabigatran ester midbody (being formula (2) compound), then with reaction solution concentrate, cooling, suction filtration, the gained solid is formula (15) compound,
Wherein, X is selected from chlorine, bromine, iodine; Said solvent is selected from acetate, ETHYLE ACETATE, THF (THF), methylene dichloride (DCM);
In second step, formula (15) compound and the reaction of formula (5) compound obtain the dabigatran ester,
Preferred; The detailed process of formula (15) compound and the reaction of formula (5) compound is: adding formula (15) compound, formula (5) compound, potassiumiodide, salt of wormwood obtain reaction solution in acetone solvent; The reaction solution heating is reacted; With the reaction solution suction filtration, the gained solid is the dabigatran ester then.
More than in each technical scheme, potassiumiodide is a catalyzer, salt of wormwood is acid binding agent.
130g formula (1) compound, 4000ml THF are dropped in the reaction flask, after stirring,, be heated to 50 ℃ of reactions at least 10 hours then in 25 ℃ of slow ethyl acetate solutions (200ml) that contain 109g bromoacetic acid acid anhydride that drip in bottle.Cooling, suction filtration; Filter cake with THF washing (2 * 100ml), obtain N-(3-acetobrom amino-4-methylamino-) benzoyl-N-(2-pyridyl)-3-alanine ethyl ester 166g after the drying, yield is 95.8%, HPLC purity is 98.5%,
1H-NMR figure is as shown in Figure 1,
13C-NMR figure is as shown in Figure 2.
1H-NMR(CDCl
3)δ:1.1(t,3H),2.7(t,2H),2.7(s,3H),4.0(m,2H),4.0(s,2H),4.3(t,2H),6.4(m,1H),6.7(m,1H),7.0(m,2H),7.2(m,1H),7.9(m,1H),8.4(m,1H)。
13C-NMR(CDCl
3)δ:14.0,28.6,30.0,33.2,44.5,60.4,109.5,121.0,121.1,122.5,127.3,129.4,137.5,146.1,148,156,165.5(NCO-),170(-COO),171(NCO)。
The present embodiment route:
It is pointed out that above-mentioned bromoacetic acid acid anhydride is also replaceable is: bromoacetic acid, bromoacetyl chloride, METHYL BROMOACETATE, promptly X is formula (A) compound of bromine.
Need to prove; N-(3-chloro acetylamino-4-methylamino-) benzoyl-N-(2-pyridyl)-3-alanine ethyl ester, N-(3-iodacetyl amino-4-methylamino-) benzoyl-N-(2-pyridyl)-3-alanine ethyl ester prepares process and said process is basic identical; It is formula (A) compound of chlorine and formula (A) compound that X is iodine that difference only is to adopt respectively X; Yield all greater than 95%, HPLC purity is all greater than 98%, and therefore concrete preparation process no longer is detailed.
46.2g N-(3-acetobrom amino-4-methylamino-) benzoyl-N-(2-pyridyl)-3-alanine ethyl ester, 600ml N (DMF), 17.6g p-aminophenyl formonitrile HCN, 5.2g potassiumiodide, 13.8g salt of wormwood are dropped into reaction flask; In 40 ℃ of reactions 10 hours, slowly be heated to 80 ℃ of reactions 2 hours again; Be cooled to room temperature afterwards, add 2500ml water precipitation 0.5 hour (in this process, stirring), suction filtration; Filter cake is with water washing (2 * 100ml); Dry back is from ETHYLE ACETATE (960ml) recrystallization; Obtain 41g formula (6) compound behind the after drying, i.e. 3-[[[2-[[(4-cyano-phenyl) amino] methyl]-1-methyl isophthalic acid H-benzoglyoxaline-5-yl] carbonyl] (pyridine-2-yl) amino] ethyl propionate, yield is 85%; Optical purity>=97%
1H-NMR figure is as shown in Figure 3.
1H-NMR(DMSO)δ:1.1(t,3H),2.7(t,2H),3.9(s,3H),3.9(m,2H),4.2(t,2H),4.5(d,2H),6.8(m,3H),7.09-7.52(m,7H),8.3(m,1H)。
Afterwards, formula (6) compound obtains formula (7) compound after hydrogenchloride and volatile salt processing, and the just own ester reaction of formula (7) compound and chloroformic acid obtains the dabigatran ester.This step belongs to prior art route 2, so this paper no longer details concrete preparation process.
The route for preparing the dabigatran ester by present embodiment:
Need to prove; The process and the said process that are prepared formula (6) compound by N-(3-chloro acetylamino-4-methylamino-) benzoyl-N-(2-pyridyl)-3-alanine ethyl ester or N-(3-iodacetyl amino-4-methylamino-) benzoyl-N-(2-pyridyl)-3-alanine ethyl ester are basic identical; And yield is all greater than 85%; Therefore optical purity no longer details concrete preparation process all greater than 97%.
Embodiment 3 directly prepares the dabigatran ester by N-(3-acetobrom amino-4-methylamino-) benzoyl-N-(2-pyridyl)-3-alanine ethyl ester
46.2g N-(3-acetobrom amino-4-methylamino-) benzoyl-N-(2-pyridyl)-3-alanine ethyl ester, 1200ml THF (THF) (also can select acetonitrile, acetone, N etc. for use), 21.4g formula (5) compound, 5.2g potassiumiodide, 27.6g salt of wormwood are dropped into reaction flask; Be heated to 30 ℃ of reactions 8 hours; Slowly be heated to 40 ℃ of reactions 1 hour (also can be heated to 20 ℃ of reaction for some time earlier, slowly be heated to 80 ℃ of reaction for some time again) again; Reaction finishes postcooling to room temperature, adds 500ml water precipitation 0.5 hour (in this process, stirring), suction filtration behind the distillation desolventizing; Filter cake is with water washing (2 * 100ml); Then from ETHYLE ACETATE (900ml) recrystallization; After the drying 51.5g dabigatran ester, i.e. 3-[[[2-[[[4-[[[(hexyloxy) carbonyl] amino] formamino] phenyl] amino] toluene]-1-methyl isophthalic acid H-benzoglyoxaline-5-yl] carbonyl] (pyridine-2-yl) amino] ethyl propionate, yield is 82.1%; Optical purity>=99%
1H-NMR figure is as shown in Figure 4.
1H-NMR(CDCl
3)δ:0.88(t,3H),1.20(t,3H),1.30-1.32(m,6H),1.55-1.59(m,2H),2.8(t,2H),3.73(s,3H),4.0-4.1(m,4H),4.4(t,2H),4.5(d,2H),6.7(d,2H),6.9(d,1H),7.1(t,1H),7.25-7.26(m,1H),7.26(dd,1H),7.31(d,1H),7.33(d,1H),7.71(td,1H),7.77(d,2H),8.4(dq,1H)。
The present embodiment route:
Need to prove; The process and the said process that are directly prepared the dabigatran ester by N-(3-chloro acetylamino-4-methylamino-) benzoyl-N-(2-pyridyl)-3-alanine ethyl ester or N-(3-iodacetyl amino-4-methylamino-) benzoyl-N-(2-pyridyl)-3-alanine ethyl ester are basic identical; Yield is all greater than 82%; Therefore optical purity no longer details concrete preparation process all greater than 99%.
Embodiment 4 prepares Beta-alanine-N-[[1-methyl isophthalic acid H-benzimidazolyl-2 radicals-brooethyl]-5-carbonyl]-N-2-pyridyl-ethyl ester (being that X is formula (15) compound of bromine) by N-(3-acetobrom amino-4-methylamino-) benzoyl-N-(2-pyridyl)-3-alanine ethyl ester
4000ml ETHYLE ACETATE (also can select acetate, THF (THF), methylene dichloride (DCM) for use), 124.5g N-(3-acetobrom amino-4-methylamino-) benzoyl-N-(2-pyridyl)-3-alanine ethyl ester are dropped in the reaction flask; Reflux is reacted; React after one day; Reaction solution is concentrated into 500ml, places-20 ℃ slowly to cool off and separate out solid, suction filtration; Filter cake is used vinyl acetic monomer: the mixing solutions washing of sherwood oil=1: 1 (2 * 50ml), after the drying Beta-alanine-N-[[1-methyl isophthalic acid H-benzimidazolyl-2 radicals-brooethyl]-5-carbonyl]-N-2-pyridyl-ethyl ester 75g, yield is 62.3%, optical purity is 97%,
1H-NMR figure is as shown in Figure 5,
13C-NMR figure is as shown in Figure 6.
1H-NMR(CDCl
3)δ:1.2(t,3H),2.2(t,2H),3.3(s,3H),4.08(m,2H),4.4(m,2H),4.6(s,2H),6.7(m,1H),7.16-7.36(m,4H),7.7(m,1H),8.4(m,1H)。
13C-NMR(CDCl
3)δ:14.1,21.0,30.4,33.2,44.6,60.4,109.0,120.9,121.3,122.3,124.6,130.4,137.3,141.2,148.9,150.4(NCN),156.1,170.6(COO),171.6(NCO)。
The present embodiment route:
Need to prove; [[1-methyl isophthalic acid H-benzimidazolyl-2 radicals-iodomethyl]-5-carbonyl]-N-2-pyridyl-ethyl ester prepares process and said process is basic identical for Beta-alanine-N-[[1-methyl isophthalic acid H-benzimidazolyl-2 radicals-chloromethyl]-5-carbonyl]-N-2-pyridyl-ethyl ester, Beta-alanine-N-; Yield all greater than 62%, optical purity is all greater than 97%, and therefore concrete preparation process no longer is detailed.
1600ml acetonitrile, 44.4g Beta-alanine-N-[[1-methyl isophthalic acid H-benzimidazolyl-2 radicals-brooethyl]-5-carbonyl]-N-2-pyridyl-ethyl ester, 17.6g p-aminophenyl formonitrile HCN, 13.8g salt of wormwood are dropped in the reaction flask, be heated to 30 ℃ of reactions 10 hours; Reaction finishes postcooling to room temperature, adds 2500ml water precipitation 0.5 hour (in this process, stirring), suction filtration; Filter cake is with water washing (2 * 100ml); Dry back is from ETHYLE ACETATE (1000ml) recrystallization; Behind the after drying 46.5g formula (6) compound, i.e. 3-[[[2-[[(4-cyano-phenyl) amino] methyl]-1-methyl isophthalic acid H-benzoglyoxaline-5-yl] carbonyl] (pyridine-2-yl) amino] ethyl propionate, yield is 96.5%; Optical purity>=98.5%
1H-NMR figure is as shown in Figure 3.
Afterwards, formula (6) compound obtains formula (7) compound after hydrogenchloride and volatile salt processing, and the just own ester reaction of formula (7) compound and chloroformic acid obtains the dabigatran ester.This step belongs to prior art route 2, so this paper no longer details detailed process.
The route for preparing the dabigatran ester by present embodiment:
Need to prove; The process and the said process that are prepared formula (6) compound by Beta-alanine-N-[[1-methyl isophthalic acid H-benzimidazolyl-2 radicals-chloromethyl]-5-carbonyl]-N-2-pyridyl-ethyl ester or Beta-alanine-N-[[1-methyl isophthalic acid H-benzimidazolyl-2 radicals-iodomethyl]-5-carbonyl]-N-2-pyridyl-ethyl ester are basic identical; Yield is all greater than 96%; Therefore optical purity no longer details concrete preparation process all greater than 98%.
Embodiment 6 directly prepares the dabigatran ester by Beta-alanine-N-[[1-methyl isophthalic acid H-benzimidazolyl-2 radicals-brooethyl]-5-carbonyl]-N-2-pyridyl-ethyl ester
1200ml acetone, 46.2g Beta-alanine-N-[[1-methyl isophthalic acid H-benzimidazolyl-2 radicals-brooethyl]-5-carbonyl]-N-2-pyridyl-ethyl ester, 21.4g formula (5) compound, 5.2g potassiumiodide, 27.6g salt of wormwood are dropped in the reaction flask, be heated to 20 ℃ of reactions 3 hours; Reaction finishes the back suction filtration; Filter cake is with water washing (3 * 200ml); Add ETHYLE ACETATE (100ml) recrystallization then; After the drying 57.2g dabigatran ester, i.e. 3-[[[2-[[[4-[[[(hexyloxy) carbonyl] amino] formamino] phenyl] amino] toluene]-1-methyl isophthalic acid H-benzoglyoxaline-5-yl] carbonyl] (pyridine-2-yl) amino] ethyl propionate, yield is 91.2%; Optical purity>=99.2%
1H-NMR figure is as shown in Figure 4.
The present embodiment route:
Need to prove; The process and the said process that are directly prepared the dabigatran ester by Beta-alanine-N-[[1-methyl isophthalic acid H-benzimidazolyl-2 radicals-chloromethyl]-5-carbonyl]-N-2-pyridyl-ethyl ester or Beta-alanine-N-[[1-methyl isophthalic acid H-benzimidazolyl-2 radicals-iodomethyl]-5-carbonyl]-N-2-pyridyl-ethyl ester are basic identical; Yield is all greater than 91.2%; Therefore optical purity no longer details concrete preparation process all greater than 99%.
Claims (10)
1. dabigatran ester midbody shown in the formula (2),
Wherein, X is selected from chlorine, bromine, iodine.
2. the said dabigatran ester of claim 1 intermediates preparation may further comprise the steps:
Formula (1) compound and formula (A) compound carry out acylation reaction and obtain the said dabigatran ester of claim 1 midbody,
3. a method for preparing the dabigatran ester is characterized in that, it is raw material that said method adopts the said dabigatran ester of claim 1 midbody.
4. according to the said method for preparing the dabigatran ester of claim 3, it is characterized in that, said method comprising the steps of: the first step obtains formula (6) compound with claim 1 said dabigatran ester midbody and the reaction of p-aminophenyl formonitrile HCN;
Second step; Formula (6) compound obtains formula (7) compound,
after hydrogenchloride and volatile salt processing
The just own ester reaction of formula (7) compound and chloroformic acid obtains the dabigatran ester.
5. according to the said method for preparing the dabigatran ester of claim 4; It is characterized in that; With the detailed process of claim 1 said dabigatran ester midbody and the reaction of p-aminophenyl formonitrile HCN be: the said dabigatran ester of adding claim 1 midbody, p-aminophenyl formonitrile HCN, potassiumiodide, salt of wormwood obtain reaction solution in solvent dimethylformamide; The reaction solution heating is reacted, and then with reaction solution cooling, aqueous precipitation, suction filtration, the gained solid is formula (6) compound.
7. according to the said method for preparing the dabigatran ester of claim 6; It is characterized in that; With the detailed process of claim 1 said dabigatran ester midbody and the reaction of formula (5) compound be: the said dabigatran ester of adding claim 1 midbody, formula (5) compound, potassiumiodide, salt of wormwood obtain reaction solution in solvent; Reaction solution is heated to 20 ℃-80 ℃ reacts, then with reaction solution concentrate, aqueous precipitation, suction filtration, the gained solid is the dabigatran ester; Said solvent is selected from THF, acetonitrile, acetone, N.
8. according to the said method for preparing the dabigatran ester of claim 3, it is characterized in that, said method comprising the steps of:
The first step is reacted the said dabigatran ester of claim 1 midbody reflux in solvent and is obtained reaction solution, then with reaction solution concentrate, cooling, suction filtration, the gained solid is formula (15) compound,
Wherein, X is selected from chlorine, bromine, iodine; Said solvent is selected from acetate, ETHYLE ACETATE, THF, methylene dichloride;
In second step, formula (15) compound and the reaction of p-aminophenyl formonitrile HCN obtain formula (6) compound,
The 3rd step; Formula (6) compound obtains formula (7) compound,
after hydrogenchloride and volatile salt processing
The just own ester reaction of formula (7) compound and chloroformic acid obtains the dabigatran ester.
9. the said according to Claim 8 method for preparing the dabigatran ester; It is characterized in that; The detailed process of formula (15) compound and the reaction of p-aminophenyl formonitrile HCN is: adding formula (15) compound, p-aminophenyl formonitrile HCN, salt of wormwood obtain reaction solution in acetonitrile solvent; The reaction solution heating is reacted, and then with reaction solution cooling, aqueous precipitation, suction filtration, the gained solid is formula (6) compound.
10. according to the said method for preparing the dabigatran ester of claim 3, it is characterized in that said method method may further comprise the steps:
The first step is reacted the said dabigatran ester of claim 1 midbody reflux in solvent and is obtained reaction solution, then with reaction solution concentrate, cooling, suction filtration, the gained solid is formula (15) compound,
Wherein, X is selected from chlorine, bromine, iodine; Said solvent is selected from acetate, ETHYLE ACETATE, THF, methylene dichloride;
In second step, formula (15) compound and the reaction of formula (5) compound obtain the dabigatran ester,
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012100780324A CN102633713B (en) | 2012-03-22 | 2012-03-22 | Dabigatran etexilate intermediate, preparation method for same and method for preparing dabigatran etexilate |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012100780324A CN102633713B (en) | 2012-03-22 | 2012-03-22 | Dabigatran etexilate intermediate, preparation method for same and method for preparing dabigatran etexilate |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102633713A true CN102633713A (en) | 2012-08-15 |
CN102633713B CN102633713B (en) | 2013-12-11 |
Family
ID=46618312
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2012100780324A Expired - Fee Related CN102633713B (en) | 2012-03-22 | 2012-03-22 | Dabigatran etexilate intermediate, preparation method for same and method for preparing dabigatran etexilate |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102633713B (en) |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103664881A (en) * | 2012-09-20 | 2014-03-26 | 天津药物研究院 | Dabigatran etexilate of crystallized variant form B as well as preparation method thereof and application |
CN103664882A (en) * | 2012-09-20 | 2014-03-26 | 天津药物研究院 | Dabigatran etexilate in crystal modification form, and preparation method and use of dabigatran etexilate |
CN103922999A (en) * | 2013-01-16 | 2014-07-16 | 上海医药工业研究院 | Preparation method for dabigatran etexilate intermediate and intermediate compound |
CN104030977A (en) * | 2013-03-07 | 2014-09-10 | 上海医药工业研究院 | Preparation method of dabigatran etexilate intermediate |
CN104177337A (en) * | 2013-05-28 | 2014-12-03 | 西藏海思科药业集团股份有限公司 | Novel intermediate of dabigatran etexilate and preparation method of novel intermediate |
WO2015027893A1 (en) * | 2013-08-26 | 2015-03-05 | 深圳翰宇药业股份有限公司 | Dabigatran etexilate synthesizing method |
CN104418805A (en) * | 2013-09-11 | 2015-03-18 | 浙江海正药业股份有限公司 | Novel dabigatran etexilate intermediate as well as preparation method and application thereof |
CN104447697A (en) * | 2014-11-24 | 2015-03-25 | 蚌埠丰原医药科技发展有限公司 | Preparation method of dabigatran etexilate intermediate |
WO2015184797A1 (en) * | 2014-06-05 | 2015-12-10 | 雅本化学股份有限公司 | N-(2-chloromethyl-1-methyl-1h-benzimidazole-5-acyl)-n-(pyridine-2-yl)-3-aminopropanoic acid ethyl ester preparation method |
CN105348148A (en) * | 2015-11-30 | 2016-02-24 | 山东新华制药股份有限公司 | Method for preparing impurity oxalate of intermediate condensation compound of pradaxa |
US20160060248A1 (en) * | 2013-03-25 | 2016-03-03 | Usv Limited | Synthesis of dabigatran |
CN105523999A (en) * | 2014-10-21 | 2016-04-27 | 重庆医药工业研究院有限责任公司 | Dabigatran etexilate intermediate synthesis method |
CN106032376A (en) * | 2015-03-17 | 2016-10-19 | 天津药物研究院有限公司 | Dabigatran etexilate of crystal variant form C, preparation method and uses thereof |
CN106032374A (en) * | 2015-03-17 | 2016-10-19 | 天津药物研究院有限公司 | Dabigatran etexilate of crystal variant form D, preparation method and uses thereof |
CN106032373A (en) * | 2015-03-17 | 2016-10-19 | 天津药物研究院有限公司 | Dabigatran etexilate of crystal variant form G, preparation method and uses thereof |
CN106032372A (en) * | 2015-03-17 | 2016-10-19 | 天津药物研究院有限公司 | Dabigatran etexilate of crystal variant form E, preparation method and uses thereof |
CN106032375A (en) * | 2015-03-17 | 2016-10-19 | 天津药物研究院有限公司 | Dabigatran etexilate of crystal variant form F, preparation method and uses thereof |
CN106928195A (en) * | 2017-03-29 | 2017-07-07 | 福建省微生物研究所 | A kind of synthetic method of Dabigatran etexilate key intermediate |
US10112901B2 (en) | 2014-07-03 | 2018-10-30 | Shanghai Institute Of Pharmaceutical Industry | Method for preparing dabigatran etexilate intermediate, and intermediate compound |
CN110981858A (en) * | 2019-12-16 | 2020-04-10 | 南通常佑药业科技有限公司 | Preparation method of anticoagulant drug dabigatran etexilate and analogue thereof |
CN114380797A (en) * | 2021-12-27 | 2022-04-22 | 山东诚汇双达药业有限公司 | Synthesis method of dabigatran etexilate |
CN116003384A (en) * | 2023-01-31 | 2023-04-25 | 宿迁盛基医药科技有限公司 | Synthesis method of dabigatran etexilate important intermediate |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1338499A (en) * | 2001-08-20 | 2002-03-06 | 清华大学 | Bispirocyclo derivative and its application in electroluminescent material |
CN101600709A (en) * | 2007-02-06 | 2009-12-09 | 贝林格尔·英格海姆国际有限公司 | The method for preparing benzimidizole derivatives |
WO2010045900A1 (en) * | 2008-10-24 | 2010-04-29 | Zentiva, K.S. | A method for the preparation of dabigatran and its intermediates |
CN102050814A (en) * | 2009-11-06 | 2011-05-11 | 北京美倍他药物研究有限公司 | Ester derivatives of dabigatran |
CN102066355A (en) * | 2008-06-16 | 2011-05-18 | 贝林格尔.英格海姆国际有限公司 | Method for producing an intermediate product of dabigatran etexilate |
-
2012
- 2012-03-22 CN CN2012100780324A patent/CN102633713B/en not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1338499A (en) * | 2001-08-20 | 2002-03-06 | 清华大学 | Bispirocyclo derivative and its application in electroluminescent material |
CN101600709A (en) * | 2007-02-06 | 2009-12-09 | 贝林格尔·英格海姆国际有限公司 | The method for preparing benzimidizole derivatives |
CN102066355A (en) * | 2008-06-16 | 2011-05-18 | 贝林格尔.英格海姆国际有限公司 | Method for producing an intermediate product of dabigatran etexilate |
WO2010045900A1 (en) * | 2008-10-24 | 2010-04-29 | Zentiva, K.S. | A method for the preparation of dabigatran and its intermediates |
CN102050814A (en) * | 2009-11-06 | 2011-05-11 | 北京美倍他药物研究有限公司 | Ester derivatives of dabigatran |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103664882A (en) * | 2012-09-20 | 2014-03-26 | 天津药物研究院 | Dabigatran etexilate in crystal modification form, and preparation method and use of dabigatran etexilate |
CN103664881A (en) * | 2012-09-20 | 2014-03-26 | 天津药物研究院 | Dabigatran etexilate of crystallized variant form B as well as preparation method thereof and application |
CN103922999A (en) * | 2013-01-16 | 2014-07-16 | 上海医药工业研究院 | Preparation method for dabigatran etexilate intermediate and intermediate compound |
CN103922999B (en) * | 2013-01-16 | 2016-05-04 | 上海医药工业研究院 | A kind of preparation method of dabigatran etcxilate intermediate and midbody compound |
CN104030977B (en) * | 2013-03-07 | 2016-05-04 | 上海医药工业研究院 | A kind of preparation method of dabigatran etcxilate intermediate |
CN104030977A (en) * | 2013-03-07 | 2014-09-10 | 上海医药工业研究院 | Preparation method of dabigatran etexilate intermediate |
US9688657B2 (en) * | 2013-03-25 | 2017-06-27 | Usv Private Limited | Synthesis of dabigatran |
US20160060248A1 (en) * | 2013-03-25 | 2016-03-03 | Usv Limited | Synthesis of dabigatran |
CN104177337A (en) * | 2013-05-28 | 2014-12-03 | 西藏海思科药业集团股份有限公司 | Novel intermediate of dabigatran etexilate and preparation method of novel intermediate |
CN104177337B (en) * | 2013-05-28 | 2019-04-23 | 海思科医药集团股份有限公司 | A kind of intermediate of dabigatran etcxilate and preparation method thereof |
WO2015027893A1 (en) * | 2013-08-26 | 2015-03-05 | 深圳翰宇药业股份有限公司 | Dabigatran etexilate synthesizing method |
CN104418839B (en) * | 2013-08-26 | 2019-02-01 | 深圳翰宇药业股份有限公司 | The synthetic method of dabigatran etcxilate |
CN104418805A (en) * | 2013-09-11 | 2015-03-18 | 浙江海正药业股份有限公司 | Novel dabigatran etexilate intermediate as well as preparation method and application thereof |
WO2015184797A1 (en) * | 2014-06-05 | 2015-12-10 | 雅本化学股份有限公司 | N-(2-chloromethyl-1-methyl-1h-benzimidazole-5-acyl)-n-(pyridine-2-yl)-3-aminopropanoic acid ethyl ester preparation method |
US10112901B2 (en) | 2014-07-03 | 2018-10-30 | Shanghai Institute Of Pharmaceutical Industry | Method for preparing dabigatran etexilate intermediate, and intermediate compound |
CN105523999A (en) * | 2014-10-21 | 2016-04-27 | 重庆医药工业研究院有限责任公司 | Dabigatran etexilate intermediate synthesis method |
CN104447697A (en) * | 2014-11-24 | 2015-03-25 | 蚌埠丰原医药科技发展有限公司 | Preparation method of dabigatran etexilate intermediate |
CN106032373A (en) * | 2015-03-17 | 2016-10-19 | 天津药物研究院有限公司 | Dabigatran etexilate of crystal variant form G, preparation method and uses thereof |
CN106032375A (en) * | 2015-03-17 | 2016-10-19 | 天津药物研究院有限公司 | Dabigatran etexilate of crystal variant form F, preparation method and uses thereof |
CN106032372A (en) * | 2015-03-17 | 2016-10-19 | 天津药物研究院有限公司 | Dabigatran etexilate of crystal variant form E, preparation method and uses thereof |
CN106032374A (en) * | 2015-03-17 | 2016-10-19 | 天津药物研究院有限公司 | Dabigatran etexilate of crystal variant form D, preparation method and uses thereof |
CN106032376A (en) * | 2015-03-17 | 2016-10-19 | 天津药物研究院有限公司 | Dabigatran etexilate of crystal variant form C, preparation method and uses thereof |
CN105348148A (en) * | 2015-11-30 | 2016-02-24 | 山东新华制药股份有限公司 | Method for preparing impurity oxalate of intermediate condensation compound of pradaxa |
CN106928195A (en) * | 2017-03-29 | 2017-07-07 | 福建省微生物研究所 | A kind of synthetic method of Dabigatran etexilate key intermediate |
CN110981858A (en) * | 2019-12-16 | 2020-04-10 | 南通常佑药业科技有限公司 | Preparation method of anticoagulant drug dabigatran etexilate and analogue thereof |
CN114380797A (en) * | 2021-12-27 | 2022-04-22 | 山东诚汇双达药业有限公司 | Synthesis method of dabigatran etexilate |
CN116003384A (en) * | 2023-01-31 | 2023-04-25 | 宿迁盛基医药科技有限公司 | Synthesis method of dabigatran etexilate important intermediate |
Also Published As
Publication number | Publication date |
---|---|
CN102633713B (en) | 2013-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102633713B (en) | Dabigatran etexilate intermediate, preparation method for same and method for preparing dabigatran etexilate | |
CN104610250A (en) | 1,2,3-thiadiazole-5-formamidine compound containing three N-heterocycles and synthesis | |
CA2648642A1 (en) | Niacin receptor agonists, compositions containing such compounds and methods of treatment | |
CN103857672B (en) | Be used to prepare 1- (4- (4- (the chloro- 2- fluoroanilino of 3,4- bis-) -7- methoxyquinazoline hydrochloride -6- base oxygroup) piperidin-1-yl) -propyl- 2- alkene -1- keto hydrochloride method and its used in intermediate product | |
CN103619832A (en) | Process for the manufacture of dabigatran etexilate and intermediates thereof | |
CN102796079B (en) | A kind of preparation method of methanesulfonic acid fluorine imatinib | |
CN104530040A (en) | Novel method for synthesizing 1,2,3-thiadiazole-5-formamidine compound | |
CN106279104B (en) | A kind of process modification method preparing amber love song Ge Lieting | |
CN104788333B (en) | 2-substituted-9,10-anthraquinone compounds, and preparation method and application thereof | |
CN101146812B (en) | Optically active ammonium salt compound, production intermediate thereof and method for producing same | |
CN103664922A (en) | Novel crystal-form azilsartan and preparation method for same | |
CN101921260B (en) | Method for preparing imatinib | |
CN103265482A (en) | Preparation method of bosutinib | |
CN103288804A (en) | Preparation method of nilotinib | |
JP6884857B2 (en) | Method for producing phenylalanine compounds | |
WO2015149656A1 (en) | 2,2'-tandem dithiazole compound, preparation method therefor, and use thereof | |
CN103626740B (en) | Synthetic method of compound | |
CN104031031A (en) | Dabigatran etexilate preparation method | |
CN104610133A (en) | Method for synthesizing novel anticancer medicine entinostat | |
CN105906607A (en) | Dabigatran etexilate synthesis method | |
Ivanov et al. | Synthesis of imatinib: a convergent approach revisited | |
CN103724360B (en) | Pyridine (or benzene) thiazolium compounds and intermediate, preparation method and application | |
CN103058982A (en) | Bifendate derivative containing halogen substituent, preparation method and application | |
CN103922999B (en) | A kind of preparation method of dabigatran etcxilate intermediate and midbody compound | |
CN105085278A (en) | Method for preparing 2-methyl-1-substituted phenyl-2-propyl amine compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131211 Termination date: 20140322 |